About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group aims to unravel the molecular mechanisms of cancer progression and metastasis to identify new diagnostic, prognostic and therapeutic targets in cancer. By combining the knowledge and availability of human tumors in the Pathology department with the expertise of the basic molecular cell biology research group, we focus on:
To evaluate the expression (nuclear and cytoplasmatic) of PTOV1 , Notch and Wnt on TMAs in c different histological types of carcinomas with low and high grades of malignancy . To correlate the inmunoexpression with classical parameters of tumor behaviour : tumoral size, grade of malignancy, vascular permeation, lymph nodes metastasis in each histological subtype and demonstrated the role of PTOV1 as predictive molecular marker in carcinomas.
(Research Biomedical Unit)
IP: Inés de Torres Ramirez
Studying in colorectal cancer mechanisms of action of the central signal transduction pathways, identify potential molecular alterations that can be used as therapeutic targets and characterize the degree of genetic inestability.
IP: Santiago Ramon y Cajal Agüeras
We have characterized the levels of activation in Cell Signalling in a spectrum of solid tumors and correlated the levels of various factors, including mTOR and downstream proteins (p70S6K, S6, 4EBP1, eIF4E) with prognosis and grade of malignancy. Also, are being characterized, at the molecular level, the factors involved in controlling the translation cap dependent and independent in malignant tumors.
The expression of mARN genes identified by Dr.R. Bernards has been studied in normal and tumor tissue of cancer patients. This study identifies for the first time, RSK4 and KIAA0828 genes as genes whose role may be relevant in cancer. The expression of these genes is being studied in protein by Western blot and immunohistochemistry. Also are characterizing the biochemical pathways where these genes may be involved.
IP: Matilde Lleonart Pajarin Collaborators: Katerin Ingrid Rojas Laimito, Irene Braña Garcia, David Virós Porcuna, Josep Castellví Vives, Marina Bataller Fernández, Juan Fernando Fuentes Cabrera, Juan Fernando Fuentes Cabrera Funding agency: Instituto de Salud Carlos III Funding: 318750 Reference: AC24/00057 Duration: 01/01/2025 - 31/12/2027
IP: Matilde Lleonart Pajarin Collaborators: Katerin Ingrid Rojas Laimito, Yoelsis Garcia Mayea, Juan Lorente Guerrero, Sergio Benavente Norza, Josep Castellví Vives, Marina Bataller Fernández, Establecimiento de una estrategia combinada en carcinoma escamoso de cabeza y cuello (HNSCC): una herramienta eficaz para supera, Juan Fernando Fuentes Cabrera, Juan Fernando Fuentes Cabrera Funding agency: Instituto de Salud Carlos III Funding: 240000 Reference: PI24/00630 Duration: 01/01/2025 - 31/12/2027
IP: Santiago Ramon y Cajal Agüeras Collaborators: Inés de Torres Ramirez, Sara Garcia Ortega, Elena Muro Blanc, Marta Cano Galietero, Vicente Peg Camara, Stefan Hummer Funding agency: Generalitat de Catalunya - Departament de Salut Funding: 189970 Reference: SLT036/24/000026 Duration: 21/12/2024 - 20/12/2026
IP: Eva Colas Ortega Collaborators: Vicente Bebia Conesa, Francesc Xavier Serra Marin, Josep Castellví Vives, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Lourdes Elena Salazar Huayna Funding agency: Generalitat de Catalunya - Departament de Salut Funding: 99946 Reference: SLT036/24/000059 Duration: 21/12/2024 - 31/12/2026
The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.
The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
Check the current rates for the services offered by the Translational Molecular Pathology research group.
Current Rates
PDF 0.25 MB
Rates Anatomia Patologica VHIR 2021
PDF 0.22 MB
